Skip to main content

Advertisement

SpringerLink
Log in

Enlighting the Shadow for Advanced Hepatocellular Carcinoma: Immunotherapy with Immune Checkpoint Inhibitors

  • Review Article
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Hepatocellular carcinoma has still been one of the cancer with increasing incidence and highest mortality rate in the world. Although many new promising developments have been defined in hepatocarcinogenesis, with a short survival the treatment of patients with advanced hepatocellular carcinoma is an emerging issue. On the recent decade, only one anti-angiogenic agent sorafenib improved overall survival with costing a hardly manageable toxicity. Novel immunotherapeutic agents, especially immune checkpoint inhibitors are on the edge of more effective but less toxic treatments for these patients. In this article the activity of immune checkpoint inhibitors, anti-CTLA-4 and anti-PD1 antibodies for the treatment of patients with advanced hepatocellular cancer will be reviewed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. International Agency for Research on Cancer. GLOBOCAN. Estimated Global Cancer Incidence, Mortality and Prevalence Worldwide in. 2012:2012. http://globocan.iarc.fr/Pages/fact_sheets_population.aspx. Accessed August 04, 2017

  2. Whittaker S, et al. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene. 2010;29:4989–5005.

    Article  CAS  Google Scholar 

  3. Llovet JM, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100:698–711.

    Article  Google Scholar 

  4. Subramanian S, et al. A review of hepatocellular carcinoma (HCC) staging systems. Chin Clin Oncol. 2013;2:33.

    Google Scholar 

  5. Llovet JM, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.

    Article  CAS  Google Scholar 

  6. Kane RC, et al. Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist. 2009;14:95–100.

    Article  CAS  Google Scholar 

  7. Cheng A-L et al. Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC). J Clin Oncol 35, 2017 (suppl; abstr 4001).

  8. Zhu AX, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015;16:859–70.

    Article  CAS  Google Scholar 

  9. Bruix J, et al. Efficacy and safety of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: results of the international, randomized phase 3 RESORCE trial. Annals of Oncol, 27, 2016 suppl LBA-3, ii140–ii141.

    Article  Google Scholar 

  10. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10.

    Article  Google Scholar 

  11. Breous E, Thimme R. Potential of immunotherapy for hepatocellular carcinoma. J Hepatol. 2011;54(4):830–4.

    Article  CAS  Google Scholar 

  12. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64.

    Article  CAS  Google Scholar 

  13. Weber J. Immune checkpoint proteins: a new therapeutic paradigm for cancer—preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol. 2010;37(5):430–9.

    Article  CAS  Google Scholar 

  14. Mizukoshi E, Nakamoto Y, Arai K, et al. Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma. Hepatology. 2011;53:1206–16.

    Article  CAS  Google Scholar 

  15. Flecken T, Schmidt N, Hild S, et al. Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma. Hepatology. 2014;59:1415–26.

    Article  CAS  Google Scholar 

  16. Umemoto Y, et al. Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy. J Gastroenterol. 2015;50(1):65–75.

    Article  CAS  Google Scholar 

  17. Grakoui A, et al. Turning on the off switch: regulation of anti-viral T cell responses in the liver by the PD-1/PD-L1 pathway. J Hepatol. 2006;45(4):468–72.

    Article  CAS  Google Scholar 

  18. Schmidt J, et al. T-cell responses in hepatitis B and C virus infection: similarities and differences. Emerg Microbes Infect. 2013;2(3):e15.

    PubMed  PubMed Central  Google Scholar 

  19. Sangro B, Gomez-Martin C, de la Mata M, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol. 2013;59:81–8.

    Article  CAS  Google Scholar 

  20. Duffy AG, Ulahannan SV, Makorova-Rusher O, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol. 2017;66:545–51.

    Article  CAS  Google Scholar 

  21. El-Khoueiry AB, et al. Phase 1/2 safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma: interim analysis of the CheckMate 040 dose-escalation study. Poster presentation at ASCO. 2016; poster 4012

  22. Sangro B, Melero I, Yau T et al. Safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma: interim analysis of dose-expansion cohorts from the phase 1/2 checkmate 040 study. In:Presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO); June 3–7, 2016; Chicago, IL, USA, poster 4078.

  23. Crocenzi T S. Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study. J Clin Oncol 35, 2017 (suppl; abstr 4013).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Oncology Department, Cukurova University, Balcali, 01330, Adana, Turkey

    Berksoy Sahin

Authors
  1. Berksoy Sahin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Berksoy Sahin.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sahin, B. Enlighting the Shadow for Advanced Hepatocellular Carcinoma: Immunotherapy with Immune Checkpoint Inhibitors. J Gastrointest Canc 48, 288–290 (2017). https://doi.org/10.1007/s12029-017-9996-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-017-9996-8

Keywords

Search

Navigation